36 completed, 2 active not recruiting, 1 terminated, 1 unknown. 19 Phase 1, 7 Phase 3, 4 Phase 2, 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 18, Terminated 1 |
| Phase 3 | 7 | Completed 7 |
| Phase 2 | 4 | Completed 4 |
| Phase 4 | 4 | Completed 2, Active not recruiting 1, Unknown 1 |
Follow tafamidis: new trials by email Literature Review of tafamidis trials Research Report on tafamidis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting Conditions Tafamidis - Healthy Adults | Phase 1 | Completed | Pfizer | 30 | 2026-05-11 | 2026-08-31 |
| A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany tafamidis 61mg (based on prescription data) - ATTR-CM (Transthyretin Amyloid Cardiomyopathy) | Active not recruiting | Pfizer | 1 | 2026-04-02 | 2026-11-06 | |
| A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions Tafamidis (Reference), Tafamidis (Test) - Healthy | Phase 1 | Terminated | Pfizer | 24 | 2026-03-23 | 2026-06-26 |
| A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults Tafamidis 61 mg free acid tablet (Test), Tafamidis 61 mg free acid capsule (Reference) - Healthy | Phase 1 | Completed | Pfizer | 22 | 2024-12-20 | 2025-05-28 |
| Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Tafamidis - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) | Completed | Pfizer | 50 | 2024-06-15 | 2026-04-29 | |
| A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India Tafamidis - Transthyretin Amyloid Cardiomyopathy | Completed | Pfizer | 6 | 2024-03-25 | 2025-11-20 | |
| A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults Tafamidis 61 mg free acid tablet (Test 1), Tafamidis 70 mg free acid tablet (Test 1), Tafamidis 61 mg free acid capsule (Reference) - Healthy | Phase 1 | Completed | Pfizer | 12 | 2024-02-27 | 2024-06-26 |
| Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation Tafamidis 61 MG - Transthyretin Cardiac Amyloidosis | Phase 4 | Active not recruiting | University of Texas Southwestern Medical Center | 25 | 2023-05-01 | 2026-06-04 |
| A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis tafamidis - Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype | Completed | Pfizer | 10 | 2023-03-08 | 2024-09-19 | |
| Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045. Tafamidis - Hereditary Transthyretin Amyloidosis (ATTRv), Polyneuropathy | Completed | Pfizer | 5 | 2022-10-24 | 2024-05-13 | |
| A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food Tafamidis free acid tablet (Test), Tafamidis meglumine capsule (Reference) - Healthy | Phase 1 | Completed | Pfizer | 22 | 2022-09-29 | 2024-06-03 |
| A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Tafamidis - Transthyretin Amyloid Cardiomyopathy | Phase 4 | Completed | Pfizer | 53 | 2021-07-22 | 2024-12-18 |
| Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy Vyndamax (tafamidis 61mg) - ATTR-CM (Transthyretin Amyloid Cardiomyopathy) | Completed | Pfizer | 110 | 2021-06-29 | 2026-08-27 | |
| The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients Tafamidis Pill - Transthyretin Amyloidosis | Phase 4 | Unknown | Peking University Third Hospital | 10 | 2021-06-01 | 2021-07-15 |
| The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients tafamidis meglumine - Transthyretin Amyloid Polyneuropathy (ATTR-PN) | Phase 4 | Completed | Pfizer | 15 | 2021-04-28 | 2024-03-12 |
| A Study to Determine the Bioequivalence of Two Doses of Tafamidis Tafamidis free acid tablet, Tafamidis meglumine capsule - Healthy | Phase 1 | Completed | Pfizer | 23 | 2020-09-17 | 2021-03-08 |
| A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics tafamidis, rosuvastatin - Healthy Volunteers | Phase 1 | Completed | Pfizer | 12 | 2020-02-06 | 2020-09-10 |
| Vyndaqel Capsules Special Investigation (ATTR-CM) Treatment for TTR amyloidosis - Transthyretin (TTR) Amyloid Cardiomyopathy | Completed | Pfizer | 1214 | 2019-10-03 | 2026-05-18 | |
| Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826) Tafamidis - Healthy Volunteers | Phase 1 | Completed | Pfizer | 9 | 2018-09-28 | 2019-02-11 |
| A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood tafamidis - Healthy | Phase 1 | Completed | Pfizer | 18 | 2017-09-29 | 2018-04-06 |
Showing 20 of 40. Sign in to see all of them.
Amyloidosis (7) · Amyloid Neuropathies, Familial (6) · Polyneuropathies (5) · Alzheimer Disease (4) · Amyloidosis, Hereditary, Transthyretin-Related (4) · Cardiomyopathies (3) · Disease Progression (1)
Pfizer (38) · Peking University Third Hospital (1) · University of Texas Southwestern Medical Center (1)
Belgium (15) · United States (13) · Germany (7) · France (6) · Brazil (5) · Japan (5) · Sweden (5) · Argentina (4) · Italy (4) · Spain (4) · Canada (3) · China (3) · Portugal (3) · United Kingdom (3) · Czechia (2)
Jeff Packman (2) · Jan Griffin, MD (1) · Jeff Packman, MBA (1) · Justin Grodin, MD (1)
PMID 31353964, PMID 32107748, PMID 27494299, PMID 30558645, PMID 29115008, PMID 32524297, PMID 33070419, PMID 34923848, PMID 36715498, PMID 37434378, PMID 37943223, PMID 38932583, PMID 40488446, PMID 42658466, PMID 23974642, PMID 24101373, PMID 25546001, PMID 25872787, PMID 28393570, PMID 28611125, PMID 28758793, PMID 28951660, PMID 30145929, PMID 32800381, PMID 33220323, PMID 33309574, PMID 33667442, PMID 33770392, PMID 33895806, PMID 34779246, PMID 35297655, PMID 35353352, PMID 36348245, PMID 36399070, PMID 36723935, PMID 36780092, PMID 37966817, PMID 38521883, PMID 38774010, PMID 38939456, PMID 39239341, PMID 39258729, PMID 40410537, PMID 40495907, PMID 40934814, PMID 42658463, PMID 42658464, PMID 42658465, PMID 42693367, PMID 42728504
2017 (3), 2015 (2), 2016 (2), 2009 (1), 2014 (1), 2023 (1)